

REVIEW

Open Access



Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

Jeffrey Cummings^{1*}, Peter Passmore², Bernadette McGuinness², Vincent Mok³, Christopher Chen⁴, Sebastiaan Engelborghs^{5,6}, Michael Woodward⁷, Sagrario Manzano⁸, Guillermo Garcia-Ribas⁹, Stefano Cappa¹⁰, Paulo Bertolucci¹¹ and Leung-Wing Chu¹²

Abstract

Background: Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a personalized care plan including lifestyle modifications to reduce the impact of modifiable risk factors (for example, blood pressure control and increased physical activity), cognitive training, dietary advice, and nutritional support. Souvenaid is a once-daily drink containing a mixture of precursors and cofactors (long-chain omega-3 fatty acids, uridine, choline, B vitamins, vitamin C, vitamin E, and selenium), which was developed to support the formation and function of neuronal membranes and synapses. Healthcare providers, patients, and carers require expert advice about the use of Souvenaid.

Methods: An international panel of experts was convened to review the evidence and to make recommendations about the diagnosis and management of MCI, identification of candidates for Souvenaid, and use of Souvenaid in real-world practice. This article provides a summary of the expert opinions and makes recommendations for clinical practice and future research.

Summary of opinion: Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with a careful clinical history. A multimodal approach is recommended; dietary and nutritional interventions should be considered alongside individualized lifestyle modifications. Although single-agent nutritional supplements have failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration. Evidence from randomized controlled trials suggests that Souvenaid should be considered as an option for some patients with early Alzheimer's disease (AD), including those with MCI due to AD (prodromal AD).

Conclusion: Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a multimodal management approach including lifestyle risk factor modification and consideration of the multinutrient Souvenaid.

Keywords: Mild cognitive impairment, Prodromal Alzheimer's disease, Nutrient, Diet, Souvenaid, Memory, Cognition

* Correspondence: cumminj@ccf.org

¹Department of Brain Health, School of Integrated Health Sciences, UNLV; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Full list of author information is available at the end of the article



Background

Mild cognitive impairment (MCI) is heterogeneous but in approximately 50% of cases represents a transitional state between normal aging and dementia [1, 2]. Early diagnosis of Alzheimer's disease (AD) in the MCI/prodromal stage presents an opportunity for interventions to improve brain health or cognitive functioning and to manage modifiable risk factors implicated in disease progression [3]. The objectives of this paper are to describe and evaluate the current identification and management of patients with MCI and to assess the role of Souvenaid (a multinutrient product) in the management of the MCI population. Since the term MCI covers a wide range of clinical presentations, an important objective was to examine the potential role of Souvenaid based on the evidence that specifically defined MCI and AD subtypes. In particular, this paper focuses on the management of patients with MCI with underlying AD pathology (e.g., prodromal AD or MCI due to AD).

Diet and nutritional status are recognized as important considerations in healthy brain aging and dementia [4]; however, clinical trial evidence for the effectiveness of single nutritional interventions in MCI remains limited [5]. Randomized clinical trials of Souvenaid have provided evidence for improvement in memory performance in subjects with early Alzheimer's disease (AD) [6, 7], but not in those with more advanced stages of AD [8]. More recently, European investigators reported encouraging findings from a trial in subjects with prodromal AD (MCI due to AD), which showed that Souvenaid had beneficial effects on cognition and function (Clinical Dementia Rating Scale-Sum of Boxes [CDR-SOB] and AD Composite Score [ADCOMS]) and on hippocampal atrophy rate [9, 10]. These data raise the possibility of considering Souvenaid as a management option for individuals diagnosed with MCI due to AD.

This paper summarizes the key clinical issues relevant to the use of Souvenaid in MCI due to AD and is based on expert insights and consensus opinions provided at a meeting held in July 2018 attended by the authors and sponsored by Nutricia. The participants represented many countries, and the consensus statement presents a global view of MCI management. After the consensus meeting, we searched ClinicalTrials.gov, WHO's International Clinical Trial Registry Platform, and PubMed to find new clinical trials and publications about nutritional interventions in subjects with MCI, using the specific search terms "Alzheimer's disease," "mild cognitive impairment," "nutrition," "Souvenaid," and "Fortasyn Connect." All authors contributed to the paper and have approved the contents.

Role of the sponsor: Nutricia paid for the meeting room but not travel costs and did not influence the

content of the consensus meeting. No Nutricia employees are listed as authors. The authors had full editorial control and made the decision to submit the final manuscript for publication.

How do physicians identify and diagnose MCI?

Individuals with MCI show a decline in cognitive functioning greater than expected for age and educational background [11]. People with MCI or their partners and other family members become aware and complain about cognitive deficits, and the initial visit to the primary care physician is usually precipitated by such complaints. Amnesic MCI typically affects recent episodic memory function and may impact several other cognitive domains including executive function, language, and visuospatial skills. People with MCI are independent with regard to the activities of daily living.

In community practice, problems with memory commonly raise the physicians' suspicions of MCI or dementia [3, 12]. Primary care physicians are encouraged to assess the patients complaining of memory loss or to refer these individuals with signs of MCI for specialist memory assessment because of the high risk of progression to dementia, most commonly AD [13]. In general, approximately 50% of MCI are associated with amyloid pathology, and 10–15% per year will transition to dementia of the AD type. The estimated 3-year cumulative incidence of AD-type dementia for individuals presenting with prodromal AD (International Working Group (IWG-2) criteria) is 61% [14]. On the other hand, a systematic review reported reversion rates from MCI to normal cognition of 8% in clinical-based studies and 25% in population-based studies [15].

US and international guidelines recommend specialist assessment using validated tests of memory and cognitive function for individuals with signs and symptoms of memory impairment or when family members or patients express concerns about potential cognitive decline [16–19]. Patient associations also play a key role in increasing awareness and encouraging early diagnosis of MCI.

The success of the strategies to delay the progression of MCI to dementia depends on early and accurate identification of people at risk of AD, including those without any evidence of significant neurodegeneration [20]. Appropriate assessment by the primary care physician including screening for cognitive problems is important to expedite referral of individuals with suspected MCI to specialists, e.g., geriatricians, psychiatrists, or neurologists [21, 22]; however, many patients are not referred [23] and some healthcare organizations may even discourage the use of specialists [24]. Timely referral and diagnosis of MCI can motivate individuals to adhere to potentially beneficial lifestyle changes and treatment interventions [11].

In the early stages, MCI may be differentiated from dementia by a preservation of functional independence and the absence of significant impairment in social or occupational functions [25]; however, the precise boundary remains elusive and there is a seamless progression from MCI to mild dementia. Further research is advocated to improve the accuracy and utility of assessment tools, such as activity of daily living (ADL) scales, and to refine screening tests at each step of the pathway to diagnosis. There is a need to improve early diagnosis of MCI allowing appropriate interventions designed to improve patient or caregiver outcomes [25].

The IWG-2 criteria define, in the context of research, prodromal AD as patients with episodic memory impairment (in most cases) and a positive cerebrospinal fluid amyloid beta (A β) and tau biomarker test or a positive amyloid beta-protein (A β) positron emission tomography (PET) scan [20, 25, 26]. In the National Institute on Aging-Alzheimer's Association criteria, among patients meeting the core clinical criteria for MCI due to dementia, the highest likelihood of underlying AD pathology is associated with positive biomarkers for both A β and neuronal injury, while an intermediate risk is associated with either a positive biomarker reflecting A β deposition with an unavailable biomarker of neuronal injury or a positive biomarker reflecting neuronal injury with an unavailable biomarker of A β [19]. Further research is important to improve early diagnosis and to facilitate more individualized management [26].

Individuals with suspected MCI should have a comprehensive medical history and physical examination to distinguish between MCI and normal aging or dementia and to identify individuals with potentially reversible (or irreversible) MCI caused by other underlying conditions [25]. Neuropsychiatric assessment is advocated by some experts because apathy, depression, and agitation are often the early symptoms of MCI [27]. An evaluation may also identify patients in early phases of non-AD conditions such as frontotemporal dementia and dementia with Lewy bodies.

Cognitive function assessments are recommended at baseline and follow-up visits [25, 28, 29]; however, the utility of available tools may be limited because many practitioners lack familiarity with them and most have administration times incompatible with the short visit times of many busy practices. Additional research is needed to harmonize neuropsychological tests for use in different languages [26]. Furthermore, the sensitivity of such instruments to detect MCI may be lower than that to detect dementia [28]. Available screening instruments are not fully appropriate for MCI assessment because they do not allow a precise quantitative definition of domain-specific impairment, for example, in episodic memory, with reference to an age- and education-matched population.

While brief screening tools are appropriate in general practice, at a specialist level, neuropsychological assessment is required. Neuropsychological tests provide valuable objective information; they can reinforce but never supplant clinical judgment and communication with the patient. The patient's clinical history is required to identify the presence of cognitive complaints, elicited from the individual, family member, or colleague. A detailed clinical history is essential to reflect inter-personal changes, specifically considering the individual's behavior and social cognition before MCI emerged. Monitoring the changes in cognitive function, memory complaints, functional abilities, and personality over time is essential, and collecting a relevant family history may contribute additional important information.

Expert opinion:

- Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with a careful clinical history. Physicians should explore the clinical history because it provides important information about the changes in individual patients, which may alert them to the emerging cognitive impairment even when an objective screening test is normal.
- Biomarkers may be used to diagnose prodromal AD in patients with MCI.

Current management of MCI

Expert reports have concluded that some medical, lifestyle, psychosocial, and nutritional interventions may prevent or delay the progression from MCI to dementia [3, 30]; however, evidence is not robust for many interventions, and no significant benefits have been shown with pharmacologic therapies such as cholinesterase inhibitors and memantine [16, 30, 31]. The Lancet Commission on Dementia Prevention suggested that 21.7% of dementia cases progressing from MCI are potentially preventable by eliminating poor diets, diabetes, and neuropsychiatric symptoms [3]. Attention to modifiable risk factors is therefore the first step for patients diagnosed with MCI [3]. Cognitive training, blood pressure management in people with hypertension, and increased physical activity should be encouraged to prevent, delay, or slow down the progression of MCI [30]. The most compelling data are for the role of exercise in reducing the risk of dementia [32, 33]. Table 1 summarizes a range of interventions that may reduce the risk of MCI and progression to dementia, and indicates, based on the expert opinion of the authors, the strength of the evidence supporting specific recommendations [3, 4, 9, 32, 34–46].

National guidelines provide generally consistent recommendations for the management of MCI [16, 17, 47].

Table 1 Lifestyle interventions recommended for MCI based on expert opinion

Intervention	Recommendation	Degree of confidence*
Medical	• Ensure blood pressure is optimal [34]	+++
	• Ensure body mass index (BMI) is optimal [35]	++
	• Ensure cholesterol level is optimal [36]	+
	• Ensure no undiagnosed diabetes or if diabetic ensure control is optimal for age [37]	+
	• Review medicines and assess for anticholinergic burden [38]	+
	• Ensure hearing loss is addressed [3]	+
	• Adopt practices to avoid head injury (use helmets, avoid unprotected contact sports) [39]	
Lifestyle	• Advise smoking reduction and cessation support [40]	+++
	• Advise limiting alcohol intake in line with currently accepted guidelines [41]	++
	• Encourage physical activity and exercise [32, 33, 42]	+++
	• Protect against head injury [39]	+
	• Encourage brain fitness activities and social connectedness	
Psychosocial	• Promote good sleep patterns and adequate sleep time	
	• Adequately treat depression and anxiety [43]	+++
	• Advise on methods of cognitive training [44]	++
	• Recommend opportunities for increasing social engagement [45]	+
Nutritional	• Reduce stress	
	• Advise on dietary principles around maintaining general health [4]	++
	• Encourage adherence to diets with some evidence of benefit, such as Mediterranean, MIND, and DASH [46]	+++
	• Recommend evidence-based nutritional supplements, such as Souvenaid, are considered [9]	+++

*Degree of confidence is based on an expert assessment of published evidence and personal experience, rather than a formal, systematic, evidence-based review: +++, high degree of confidence with strong supporting evidence from randomized controlled trials; ++, good degree of confidence with supporting evidence; +, fair degree of confidence with some supporting evidence

Pharmacologic interventions with AD drugs are generally not recommended for patients with MCI but may be considered if there is biomarker evidence of AD, although this opinion is based on limited clinical trial evidence [48]. Changes to lifestyle and diet are encouraged, with the proviso that benefits may be modest [49]. Epidemiological studies have shown an association between diets with high antioxidant content, such as the Mediterranean diet, and a decreased risk of dementia [50], MCI [51], and cognitive decline [52–56] in older adults. The evidence also suggests that multimodal intervention in lifestyle risk factors is more appropriate than focusing on single parameters [56, 57]; single nutritional supplements are not recommended because of insufficient evidence of clinical benefit [5].

Expert opinion:

- A multimodal approach is recommended; dietary and nutritional interventions should be considered alongside individualized lifestyle modifications.
- Pharmacologic therapy, except for the treatment of depression or other neuropsychiatric symptoms, is usually not appropriate for patients diagnosed with MCI.

Rationale for nutritional interventions

The association between diet, nutritional status, and healthy brain aging has provided a rationale for the investigation of supplements to improve cognitive function in patients with MCI or AD [4, 58]. Single-agent nutrient supplements tested include vitamin E [59], vitamin C [60], B vitamins [61–63], vitamin D [64], flavonoids [65], carotenoids [65, 66], and omega-3 fatty acids [67]. Based on the existing trials, however, there is insufficient evidence to support the use of single-agent nutrients to modify the course of cognitive decline in patients with MCI [5]. The body of evidence showing the role of dietary and nutritional factors in MCI and AD is constantly evolving and has been reviewed extensively in recent papers [68–70]. Despite the failure of numerous studies to show benefits for single-agent nutrient supplements [5], there are compelling reasons to consider a nutritional approach in conjunction with lifestyle interventions for the management of MCI [71], for example, to enhance the supply of precursors required to make neuronal membranes and synapses [72].

The neuronal membranes are composed of a phospholipid bilayer containing cholesterol and other lipids [73, 74]. Changes in the composition of these lipids and phospholipids are associated with several neurological

and psychiatric diseases [75]. There is a growing consensus on changed phospholipid profiles in patients with AD [76], reflecting disturbed phospholipid metabolism [77], which occurs early in the AD process [78, 79]. Phospholipids are affected by several of the lifestyle interventions recommended in the management of MCI, including exercise [80], smoking cessation [81], sleep quality [82], and dietary modification [83]. The reported benefits of combining multimodal lifestyle interventions [56, 57] could be mediated at least in part by cumulative effects on normalizing phospholipid metabolism. By improving phospholipid metabolism, lifestyle interventions may help to preserve neuronal functions and maintain cognitive performance. Evidence suggests that key nutrients required for phospholipid synthesis are lower in the blood and cerebrospinal fluid of patients with MCI [84] and such nutritional deficiencies may impair the brain's ability to maintain neuronal functions.

The metabolic pathway responsible for producing brain phospholipids can be positively influenced by supplying a combination of nutritional precursors and cofactors (reviewed in Wurtman et al. [85]). Nutrients appear to act synergistically, which suggests that a multi-nutrient approach could be more effective than supplementation with a single nutrient [71].

Several studies have shown that nutrient intervention can increase plasma levels of nutrients involved in phospholipid synthesis, but most failed to demonstrate clinical benefits [86–96]. More beneficial effects may be achieved by addressing the complete specific nutritional requirement for phospholipid synthesis, including phospholipid precursors, nutritional cofactors, and antioxidants.

Expert opinion:

- Although single-agent nutritional supplements have failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration.

Clinical trials of Souvenaid

Souvenaid is a once-daily drink containing a mixture of precursors and cofactors (long-chain omega-3 fatty acids, uridine, choline, B vitamins, vitamin C, vitamin E, and selenium) necessary for the formation and function of neuronal membranes and synapses [71].

The first clinical trials of Souvenaid (Table 2) showed encouraging effects on memory performance in patients with mild AD dementia. Souvenaid was associated with a statistically significant improvement in memory performance in patients with mild and very mild AD dementia, observed over 12 weeks in Souvenir I and 24 weeks in Souvenir II [6, 7], and patients continued to exhibit improved memory for up to 48 weeks [97]. Another

trial in patients with mild-moderate AD dementia showed that Souvenaid could be taken safely with standard AD drugs; however, no significant cognitive improvements were demonstrated [8]. These preliminary data suggested that the benefits of Souvenaid were most likely to be seen at the early end of the AD spectrum, and subsequently, an independent trial group (LipiDiDiet) designed a trial in patients with MCI due to AD (prodromal AD) [9].

In 2009, the European LipiDiDiet Group started a 24-month randomized, controlled, double-blind, parallel-group, multicenter trial in patients with prodromal AD [9]. Participants were randomly assigned (1:1) to active product (125 ml once a day Souvenaid) or control product and were not receiving cholinesterase inhibitors at baseline. The primary endpoint was a change in a neuropsychological test battery (NTB; composite *z*-score based on the Consortium to Establish a Registry for Alzheimer's Disease [CERAD] 10-word list learning immediate recall, CERAD 10-word delayed recall, CERAD 10-word recognition, category fluency, and letter digit substitution test). Although the intervention had no significant effect on the primary endpoint over 2 years, cognitive decline in this trial population was much lower than expected in both the treatment and the placebo groups; therefore, the primary endpoint was inadequately powered. The LipiDiDiet trial showed significant differences in secondary endpoints. Significant benefits were reported for Souvenaid in the CDR-SOB and ADCOMS [9, 10]. In addition, a per-protocol analysis, which excluded patients with major protocol violations (most commonly, failure to comply with study product intake), showed a benefit in episodic memory (three-item memory composite *z*-score); this was not significant in the intention-to-treat analysis. Brain imaging with MRI showed significant reduction of hippocampal atrophy and less expansion of ventricular volume in patients taking Souvenaid.

Taken together, the 4 randomized controlled trials including a total of 1332 patients with prodromal AD or mild-moderate AD dementia (Table 2) showed that Souvenaid was well tolerated [6–9]. Only 1 of these trials (LipiDiDiet trial) specifically studied the use of Souvenaid in MCI due to AD (prodromal AD). Adverse events reported in the LipiDiDiet trial are shown in Additional file 1: Table S1.

An effect size analysis was done to see whether the effects of Souvenaid are clinically detectable in patients with early AD [98]. Effect sizes >0.2 are considered large enough to be clinically meaningful [99]. The calculated effect sizes (Cohen's *d* statistic) were 0.21 (95% confidence intervals $-0.06, 0.49$) for the primary outcome in Souvenir II (NTB memory *z*-score) and 0.20 (0.10, 0.34) for the co-primary outcome of Souvenir I (Wechsler

Table 2 Summary of randomized clinical trials of Souvenaid in patients with prodromal AD (MCI due to AD), mild AD dementia, and mild-moderate AD dementia

Population	Prodromal AD ^a	Mild AD dementia ^b	Mild AD dementia ^c	Mild-moderate AD dementia ^d
Reference	LipiDiet [9]	Souvenir II [7, 97]	Souvenir I [6]	S-Connect [8]
AD drug use	No	No	No	Yes
Intervention duration	24 months	24 weeks (+ 24-week extension)	12 weeks (+ 12-week extension)	24 weeks
No. of patients randomized	311	259	225	527
Country	Finland, Germany, The Netherlands, Sweden	The Netherlands, Germany, Belgium, Spain, Italy, France	The Netherlands, Germany, Belgium, UK, USA	USA
Ethnic origin	99% White	Not stated	Not stated	94% White
Mean age (years)	71	73.8	73.7	76.7
Male/female (%)	49.5/50.5	51/49	50/50	48/52
Average MMSE	26.6	25	23.9	19.5
Primary outcomes	NTB composite score measuring cognition	NTB memory domain composite score	WMS-r delayed verbal recall measuring episodic memory Modified 13-item ADAS-cog assessing cognition	11-item ADAS-cog measuring cognition
Secondary outcomes	CDR-SOB Brain volumes based on MRI (3D T1-weighted anatomical scans of total hippocampal, whole brain, and ventricular volumes Progression to dementia Nutritional blood parameters	NTB executive function domain NTB total composite score DAD EEG Nutritional blood parameters	ADCS-ADL WMS-r immediate verbal recall CIBIC-plus NPI QOL-AD Nutritional blood parameters	Cognitive test battery (Digit Span-WMS, concept shifting test, letter digit substitution test, and category fluency) ADCS-ADL CDR-SOB Nutritional blood parameters

^aADAS-cog Alzheimer's Disease Assessment Scale-cognitive subscale, ADCS-ADL Alzheimer's Disease Co-operative Study-Activities of Daily Living, CDR-SOB Clinical Dementia Rating Sum of Boxes, CIBIC-plus Clinician Interview-Based Impression of Change plus Caregiver Input, CSF cerebrospinal fluid, DAD Disability Assessment for Dementia Scale, EEG electroencephalography, MEG magnetoencephalography, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, NPI neuropsychiatric inventory, NTB neuropsychological test battery, QOL-AD Quality of Life in Alzheimer's Disease, WMS-r Wechsler Memory Scale-revised

^bProdromal AD as defined by episodic memory disorder (performance below one standard deviation on two of eight cognitive tests [at least one on memory]) and evidence for underlying AD pathology based on positive findings from at least one of the following diagnostic tests: CSF, MRI, and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET analysis

^cProbable AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, an MMSE score of \geq 20, and recent magnetic resonance imaging (MRI) or computed tomography (CT) scan had shown no evidence of any other potential causes of dementia

^dProbable AD according to the NINCDS-ADRDA criteria, a MMSE score of 20–26, and a recent MRI or CT scan compatible with AD

^eProbable AD according to the NINCDS-ADRDA criteria, a MMSE score between 14 and 24 inclusive, and use of US Food and Drug Administration-approved AD medication on a stable dose for at least 4 months prior to baseline

Memory Scale delayed recall). The number needed to treat (NNT) values for Souvenaid were 6 for Wechsler Memory Scale-revised (WMS-r) delayed memory (> 0) in Souvenir I, 9 for NTB memory (≥ 0.3), and 21 for NTB memory (≥ 0.0) in Souvenir II. The low NNT and high number needed to harm (NNH) indicated a favorable harm-to-benefit ratio for Souvenaid in patients with mild AD dementia [98]. Additional data from the LipiDiDiet trial showed effect sizes of 0.17 for the primary NTB endpoint and 0.33 for the secondary CDR-SOB endpoint, with NNT values of 10 and 6, respectively, and high NNH values [9]. Effect size analyses help to inform the discussion about whether interventional effects of Souvenaid may be considered clinically meaningful and suggest that benefits are greatest when using Souvenaid early in the course of AD.

A meta-analysis of published clinical trials showed Souvenaid was associated with improvements in verbal recall in patients at early stages of AD dementia. Souvenaid had no detected beneficial effects on functional ability, behavior, or global clinical change over the broad spectrum of AD [100]. However, this meta-analysis was not based on individual patient data and did not include data from the LipiDiDiet trial.

The data from randomized controlled trials corroborate the putative mode of action of Souvenaid, i.e., improving the supply of nutrients required for phospholipid metabolism and to support neuronal structure and function [85]. Measurements of nutritional biomarkers showed increased nutrient levels [9, 97] and phosphatidylcholine-docosahexaenoic acid levels [76] in the bloodstream and increased choline levels and markers of phospholipid synthesis in the brain revealed by magnetic resonance spectroscopy [101]. Furthermore, electroencephalography showed improved functional network connectivity in patients with early AD [102]. An exploratory study, with a small sample size and unbalanced study groups, did not show any treatment effects using the novel technique of magnetoencephalography [103]. Brain imaging did show a reduced brain atrophy rate in patients with prodromal AD, suggesting a potential effect on the disease process [9]. A post hoc analysis of data from the LipiDiDiet trial showed a correlation between the preservation of hippocampal volume and memory and CDR-SB [104]. Changes in biomarkers, particularly in hippocampal volume, support the proposed mode of action of Souvenaid, but the relation between the biomarkers and clinical outcomes remains hypothetical. Currently, there is insufficient evidence to show that nutritional biomarkers could be used to indicate the efficacy of Souvenaid. Further clinical trial evidence may support the hypotheses generated.

Real-world data and patient experience programs have also reported benefits for Souvenaid in patients with

cognitive impairment and mild AD, including increased motivation and social engagement, improved energy levels, physical and mental resilience, and improvements in mood, cognition, and memory associated with a return to functional tasks and hobbies [105–110]. One study showed that Souvenaid was effective on behavioral and functional deficits [105], while another reported improvements in depression, anxiety, and apathy [109]. Furthermore, caregivers reported benefits in the Subjective Changing Scale (SCS) in patients with MCI at high risk of progression to AD taking Souvenaid [110]. It is important to note that data from these studies are not as strong as the data from randomized controlled trials.

Expert opinion:

- Evidence from randomized controlled trials suggests that Souvenaid should be considered as a management option for some patients with early AD, including MCI.

Who may benefit from Souvenaid?

Randomized controlled trials investigated Souvenaid across a spectrum of patients with AD, ranging from prodromal AD to mild-moderate AD dementia, and the data showed that the benefits are greater when the product is used early in the disease course. In the LipidiDiet study, pre-specified subgroup analyses showed the benefits of Souvenaid on cognition, memory, and hippocampal volume were greater among patients with very mild disease (MMSE ≥ 26) [9]. An exploratory analysis of these data showed that the effect of Souvenaid on CDR-SOB increased with higher baseline MMSE scores. In patients with a diagnosis of dementia, randomized controlled trials of Souvenaid showed significant benefits in mild AD [6, 7], but not in drug-treated mild-moderate AD dementia (MMSE 14–24) [8].

The low NNT and excellent NNH values together with high rates of long-term product adherence show that Souvenaid is a viable option for use in early-stage disease, including MCI due to AD. Biomarkers should be used to support the diagnosis of MCI due to AD (prodromal AD) because the only randomized controlled trial data showing clinical benefit were obtained in this population; subjects in the LipiDiDiet trial had to have evidence for the underlying AD pathology based on the positive findings from at least one diagnostic test (CSF, MRI, and ^{18}F -FDG PET) [9]. No studies are available on the effects of Souvenaid in MCI patients with a different diagnostic type. At present, there is insufficient evidence to show that biomarkers could be used at an individual level to see if patients are benefiting from Souvenaid.

Expert opinion:

- Souvenaid should be considered as an option for patients with a diagnosis of MCI due to AD pathology (prodromal AD) or mild AD dementia.
- Souvenaid is not recommended for patients with moderate or advanced AD dementia.

For how long may Souvenaid be taken?

Based on the findings of the LipiDiDiet trial [9], patients with MCI due to AD should expect to take Souvenaid for at least 2 years. They may continue to take Souvenaid every day until the physician determines that there is no evidence of benefit, intolerance develops, or patients progress to moderate AD. The benefit can be assessed at each clinic visit using objective tools to assess cognitive functions and subjective reports from the patient and carers. Such information should be considered in the context of the patient's clinical history.

Souvenaid is well tolerated; however, any features of poor tolerability by individual patients could disrupt adherence and lead to discontinuation. In the LipiDiDiet trial, reported adverse events such as headache and diarrhea were similar in Souvenaid and control groups, and dropout rates due to adverse events were not significantly different between the groups (6% vs 4%, respectively; $p = 0.437$).

It is important to inform patients about the need to adhere to long-term daily intake because the clinical trial data show that the greatest clinical benefits were seen among patients taking the product per protocol [7]. Patients should also be informed about the financial implications of using Souvenaid, especially when they are self-funding, as most will be.

When starting Souvenaid, patients and their caregivers should be given realistic advice about their expected disease course. The risk of progression to AD dementia is significantly higher among individuals with prodromal AD (IWG-2 criteria) compared with those without prodromal AD (61% vs 22% progression at 3 years; hazard ratio 4.0 [95% confidence intervals 3.0–5.2]) [14]. Furthermore, progression to AD is more likely in patients with prodromal AD than in those with other forms of MCI [111]. The LipiDiDiet trial continues to monitor the progression rates in subjects continuing to take Souvenaid compared with controls; however, currently, there is not enough evidence to conclude that Souvenaid decreases the rate of progression from MCI to dementia.

Patients progressing from MCI to mild AD dementia may continue to benefit from Souvenaid [6, 7]. Continuing Souvenaid is not recommended for patients progressing from early to moderate or severe AD dementia [8].

Expert opinion:

- Patients with MCI should take Souvenaid for 2 years or longer if there is evidence of continuing benefit.

- Souvenaid should be stopped if intolerance develops, the patient is no longer benefitting, or they progress to moderate-severe AD.

Implications for practice, policy, and/or research

Early identification of individuals at risk of progression from MCI to AD dementia is crucial to facilitate patient management at a time when pathological changes and clinical deficits are not yet severe [20]. Primary care physicians have an important role to play in referring individuals with suspected MCI for specialist assessment. Currently, however, there are no treatment options recommended in national guidelines to slow or reverse the progression of MCI to dementia. Data suggest that management of patients with a diagnosis of MCI requires a multimodal approach involving lifestyle changes to reduce the effects of modifiable risk factors (hearing loss, obesity, hypertension, smoking, depression, physical inactivity, social isolation, and diabetes mellitus) [3] and to promote healthy nutrition [4, 58].

Encouraging patients to adopt a healthy lifestyle and diet to support cognitive function is an important first step in the management of patients with MCI [4, 58]. In addition, patients should be provided with information about the multinutrient product Souvenaid, which may be considered as an option for patients with MCI; however, it is important to make patients aware that clinical trial data were obtained in patients with a diagnosis of MCI with AD pathology.

Conclusion

The consensus opinion of the expert panel is summarized in Table 3. Additional research is required to refine the identification of patients most likely to benefit from Souvenaid and to assess response and clinical benefit during long-term management.

Table 3 Summary of expert opinion on MCI

-
- Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with a careful clinical history. Physicians should explore the clinical history because it provides important information about the changes in individual patients, which may alert them to the emerging cognitive impairment even when an objective screening test is normal.
 - A multimodal approach is recommended; dietary and nutritional interventions should be considered alongside individualized lifestyle modifications. Pharmacologic therapy, except for the treatment of depression or other neuropsychiatric symptoms, is usually not appropriate for patients diagnosed with MCI.
 - Although single-agent nutritional supplements have failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration.
 - Evidence from randomized controlled trials suggests that Souvenaid should be considered as a management option for patients with early AD, including MCI.
 - Souvenaid should be considered as an option for patients with a diagnosis of MCI due to AD (prodromal AD) or mild AD dementia. Souvenaid is not recommended for patients with moderate or advanced AD dementia.
 - Patients with MCI should take Souvenaid for 2 years or longer if there is evidence of continuing benefit.
-

Additional file

Additional file 1: Table S1. LipiDiDiet trial adverse events in participants randomly assigned to Souvenaid or control [9]. (DOCX 13 kb)

Abbreviations

AD: Alzheimer's disease; ADAS-cog: Alzheimer's Disease Assessment Scale-cognitive subscale; ADCOMS: Alzheimer's Disease Composite Score; ADCS-ADL: Alzheimer's Disease Co-operative Study-Activities of Daily Living; Aβ: Amyloid beta; CDR-SOB: Clinical Dementia Rating Sum of Boxes; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CIBIC-plus: Clinician Interview-Based Impression of Change plus Caregiver Input; CSF: Cerebrospinal fluid; DAD: Disability Assessment for Dementia Scale; EEG: Electroencephalography; MCI: Mild cognitive impairment; MEG: Magnetoencephalography; MMSE: Mini-Mental State Examination; MRI: Magnetic resonance imaging; NNH: Number needed to harm; NNT: Number needed to treat; NPI: Neuropsychiatric inventory; NTB: Neuropsychological test battery; PET: Positron emission tomography; QOL-AD: Quality of Life in Alzheimer's Disease; WMS-r: Wechsler Memory Scale-revised

Acknowledgements

A meeting held in July 2018 attended by the authors was sponsored by Nutricia (The Netherlands). The sponsor funded editorial services for the manuscript, provided by Tim Kelly, Medi-Kelsey Limited.

Authors' contributions

JC, PP, BM, VM, CC, SE, MW, SM, GGR, SC, PB, and LWC attended an expert panel meeting in July 2018, chaired by JC, which was used as the basis for writing this manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by Nutricia Research, The Netherlands.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

Dr. Cummings has provided consultation to Acadia, Accera, Actinogen, Alkahest, Allergan, Alzheon, Avanir, Axsome, BioOasis, Biogen, Bracket, Denali, Diadem, EIP Pharma, Eisai, Forum, Genentech, Green Valley, Grifols, Hisun, Kyowa Kirin, Lilly, Lundbeck, Medavante, Merck, Otsuka, Pain Therapeutics, Proclera, QR, Resverlogix, Roche, Samus, Takeda, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in Prana, Neurokos, ADAMAS, MedAvante, QR pharma, Samus, Green Valley, and BioOasis. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.

Professor Passmore has provided consultation to Pfizer, Eisai, J&J, Shire, Novartis, Lundbeck, Otsuka, MSD, and Nutricia.

Dr. Chen has provided consultation to Accera, Allergan, Baxter, Danone, Eisai, Janssen, Lundbeck, Moleac, Novartis, Otsuka, Pfizer, and Wyeth pharmaceutical companies.

Professor Cappa has provided consultation to Eli Lilly, Roche, Biogen, and Nutricia.

All other authors declare that they have no competing interests.

Author details

¹Department of Brain Health, School of Integrated Health Sciences, UNLV, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

²Centre for Public Health, Institute of Clinical Sciences, Queens University Belfast, Belfast, UK. ³Therese Pei Fong Chow Research Center for Prevention of Dementia, Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Department of Medicine and Therapeutics, The Chinese

University of Hong Kong, Hong Kong Special Administrative Region, China.

⁴Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Memory Aging and Cognition Centre, National University Health System, Singapore, Singapore.

⁵Reference Centre for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium. ⁶Department of Neurology, Centre for Neurosciences, UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

⁷Department of Medicine, The University of Melbourne, Austin Health, Melbourne, Victoria, Australia. ⁸Neurology Department, Infanta Leonor Hospital, Madrid, Spain. ⁹Servicio de Neurología, Hospital Universitario Ramón y Cajal, Madrid, Spain. ¹⁰University School for Advanced Studies IUSS, Pavia and IRCCS Istituto Centro, S. Giovanni di Dio, Brescia, Italy. ¹¹Service of Cognitive and Behavioral Neurology, Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil.

¹²Department of Medicine, The University of Hong Kong and Hong Kong Brain Memory Centre, Hong Kong Special Administrative Region, China.

Received: 16 April 2019 Accepted: 6 August 2019

Published online: 17 August 2019

References

- Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. *Acta Psychiatr Scand.* 2009;119(4):252–65.
- Petersen RC, et al. Current concepts in mild cognitive impairment. *Arch Neurol.* 2001;58(12):1985–92.
- Livingston G, et al. Dementia prevention, intervention, and care. *Lancet.* 2017;390(10113):2673–734.
- Vandewoude M, et al. Healthy brain ageing and cognition: nutritional factors. *Eur Geriatr Med.* 2016;7(1):77–85.
- Munoz Fernandez SS, Ivanauskas T, Lima Ribeiro SM. Nutritional strategies in the management of Alzheimer disease: systematic review with network meta-analysis. *J Am Med Dir Assoc.* 2017;18(10):897 e13–e30.
- Scheltens P, et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. *Alzheimers Dement.* 2010;6(1):1–10 e1.
- Scheltens P, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. *J Alzheimers Dis.* 2012;31(1):225–36.
- Shah RC, et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. *Alzheimers Res Ther.* 2013;5(6):59.
- Soininen H, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. *Lancet Neurol.* 2017;16(12):965–75.
- Hendrix SB, et al., editors. ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer's disease 11th Clinical trials on Alzheimer's Disease; 2018 October 24–27; Barcelona. Abstr LB11.
- Petersen RC, et al. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol.* 1999;56(3):303–8.
- Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. *Int J Geriatr Psychiatry.* 2000;15(11):983–91.
- Behrman S, Valkanova V, Allan CL. Diagnosing and managing mild cognitive impairment. *Practitioner.* 2017;261(1804):17–20.
- Vos SJ, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. *Brain.* 2015 May;138(Pt 5):1327–38.
- Canevelli M, et al. Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis. *J Am Med Dir Assoc.* 2016;17(10):943–8.
- Petersen RC, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(3):126–35.
- Pottie K, et al. Recommendations on screening for cognitive impairment in older adults. *CMAJ.* 2016;188(1):37–46.
- National Collaborating Centre for Mental Health. The Dementia Care Pathway. Full implementation guidance. London: National Collaborating Centre for Mental Health; 2018. <https://www.rcpsych.ac.uk/improving-care/nccmh/care-pathways/dementia>. Accessed 1 Dec 2018.
- Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on

- Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270–9.
20. Yassine HN. Targeting prodromal Alzheimer's disease: too late for prevention? *Lancet Neurol*. 2017;16(12):946–7.
 21. Janssen J, et al. How to choose the most appropriate cognitive test to evaluate cognitive complaints in primary care. *BMC Fam Pract*. 2017;18(1):101.
 22. Yokomizo JE, Simon SS, Bottino CM. Cognitive screening for dementia in primary care: a systematic review. *Int Psychogeriatr*. 2014;26(11):1783–804.
 23. Ritchie CW, et al. Quantifying the diagnostic pathway for patients with cognitive impairment: real-world data from seven European and North American countries. *J Alzheimers Dis*. 2018;62(1):457–66.
 24. Dubois B, et al. Timely diagnosis for Alzheimer's disease: a literature review on benefits and challenges. *J Alzheimers Dis*. 2016;49(3):617–31.
 25. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAMA*. 2014;312(23):2551–61.
 26. Frisoni GB, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *Lancet Neurol*. 2017;16(8):661–76.
 27. Geda YE, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. *Am J Psychiatry*. 2014; 171(5):572–81.
 28. Lin JS, et al. Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2013; 159(9):601–12.
 29. Tsoi KK, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. *JAMA Intern Med*. 2015;175(9):1450–8.
 30. Kane RL, et al. Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia. Agency for Healthcare Research and Quality (US); 2017. <http://www.ncbi.nlm.nih.gov/books/NBK442425/>. Accessed 1 Dec 2018.
 31. Fink HA, et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. *Ann Intern Med*. 2018;168(1):39–51.
 32. Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385(9984):2255–63.
 33. Panza GA, et al. Can exercise improve cognitive symptoms of Alzheimer's disease? *J Am Geriatr Soc*. 2018;66(3):487–95.
 34. Kjeldsen SE, et al. Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. *Blood Press*. 2018;27(5):247–8.
 35. Cournot M, et al. Relation between body mass index and cognitive function in healthy middle-aged men and women. *Neurology*. 2006;67(7):1208–14.
 36. Solomon A, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. *Neurology*. 2007;68(10):751–6.
 37. Rawlings AM, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. *Ann Intern Med*. 2014;161(11):785–93.
 38. Risacher SL, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol*. 2016;73(6):721–32.
 39. Li Y, et al. Head injury as a risk factor for dementia and Alzheimer's disease: a systematic review and meta-analysis of 32 observational studies. *PLoS One*. 2017;12(1):e0169650.
 40. Durazzo TC, et al. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. *Alzheimers Dement*. 2014;10(3 Suppl):S122–45.
 41. Topiwala A, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. *BMJ*. 2017; 357:j2353.
 42. Wang C, et al. Non-pharmacological interventions for patients with mild cognitive impairment: a meta-analysis of randomized controlled trials of cognition-based and exercise interventions. *J Alzheimers Dis*. 2014;42(2):663–78.
 43. Orgeta V, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. *Br J Psychiatry*. 2015;207(4):293–8.
 44. Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy older adults and people with mild cognitive impairment: a systematic review. *Ageing Res Rev*. 2013;12(1):263–75.
 45. Hughes TF, et al. Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT study. *Int Psychogeriatr*. 2013; 25(4):587–95.
 46. Solfrizzi V, et al. Relationships of dietary patterns, foods, and micro- and macronutrients with Alzheimer's disease and late-life cognitive disorders: a systematic review. *J Alzheimers Dis*. 2017;59(3):815–49.
 47. Lautenschlager NL, et al. Physical activity guidelines for older Australians with mild cognitive impairment or subjective cognitive decline. Melbourne: Dementia Collaborative Research Centres; 2018. <http://www.dementia.unsw.edu.au/>. Accessed 1 Dec 2018
 48. Petersen RC, et al. Randomized controlled trials in mild cognitive impairment: sources of variability. *Neurology*. 2017;88(18):1751–8.
 49. McGrattan AM, et al. The effect of diet, lifestyle and/or cognitive interventions in mild cognitive impairment: a systematic review. *Proc Nutri Soc*. 2017;76(OCE3):E114.
 50. Scarmeas N, et al. Mediterranean diet and risk for Alzheimer's disease. *Ann Neurol*. 2006;59(6):912–21.
 51. Scarmeas N, et al. Mediterranean diet and mild cognitive impairment. *Arch Neurol*. 2009;66(2):216–25.
 52. Feart C, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. *JAMA*. 2009;302(6):638–48.
 53. Tangney CC, et al. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. *Am J Clin Nutr*. 2011;93(3):601–7.
 54. Tsigoulis G, et al. Adherence to a Mediterranean diet and risk of incident cognitive impairment. *Neurology*. 2013;80(18):1684–92.
 55. Wengreen H, et al. Prospective study of dietary approaches to stop hypertension- and Mediterranean-style dietary patterns and age-related cognitive change: the Cache County Study on Memory, Health and Aging. *Am J Clin Nutr*. 2013;98(5):1263–71.
 56. Lehtisalo J, et al. Nutrient intake and dietary changes during a 2-year multi-domain lifestyle intervention among older adults: secondary analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomised controlled trial. *Br J Nutr*. 2017;118(4):291–302.
 57. Anastasiou CA, et al. Mediterranean lifestyle in relation to cognitive health: results from the HELIAD Study. *Nutrients*. 2018;10(10):1557. <https://doi.org/10.3390/nu10101557>.
 58. Radd-Vagenas S, et al. Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials. *Am J Clin Nutr*. 2018;107(3):389–404.
 59. Farina N, et al. Vitamin E for Alzheimer's dementia and mild cognitive impairment. *Cochrane Database Syst Rev*. 2017. <https://doi.org/10.1002/14651858.CD002854.pub5>.
 60. Harrison FE. A critical review of vitamin C for the prevention of age-related cognitive decline and Alzheimer's disease. *J Alzheimers Dis*. 2012;29(4):711–26.
 61. Clarke R, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. *Am J Clin Nutr*. 2014;100(2):657–66.
 62. Li MM, et al. Efficacy of vitamins B supplementation on mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *Curr Alzheimer Res*. 2014;11(9):844–52.
 63. Zhang DM, et al. Efficacy of vitamin B supplementation on cognition in elderly patients with cognitive-related diseases. *J Geriatr Psychiatry Neurol*. 2017;30(1):50–9.
 64. Shen L, Ji HF. Vitamin D deficiency is associated with increased risk of Alzheimer's disease and dementia: evidence from meta-analysis. *Nutr J*. 2015;14:76.
 65. Crichton GE, Bryan J, Murphy KJ. Dietary antioxidants, cognitive function and dementia—a systematic review. *Plant Foods Hum Nutr*. 2013;68(3):279–92.
 66. Li FJ, Shen L, Ji HF. Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis. *J Alzheimers Dis*. 2012;31(2):253–8.
 67. Canhada S, et al. Omega-3 fatty acids' supplementation in Alzheimer's disease: a systematic review. *Nutr Neurosci*. 2018;21(8):529–38.
 68. Hill E, et al. Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis. *Neurobiol Aging*. 2019;76:45–52.
 69. Scarmeas N, et al. Nutrition and prevention of cognitive impairment. *Lancet Neurol*. 2018;17:1006–15.
 70. Pistollato F, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: a focus on human studies. *Pharmacol Res*. 2018;131:32–43.
 71. van Wijk N, et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. *J Alzheimers Dis*. 2014;38(3): 459–79.
 72. Engelborghs S, et al. Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. *Acta Clin Belg*. 2014;69(1):17–24.

73. Bozek K, et al. Organization and evolution of brain lipidome revealed by large-scale analysis of human, chimpanzee, macaque, and mouse tissues. *Neuron*. 2015;85(4):695–702.
74. Sastry PS. Lipids of nervous tissue: composition and metabolism. *Prog Lipid Res*. 1985;24(2):69–176.
75. Lauwers E, Goodchild R, Verstreken P. Membrane lipids in presynaptic function and disease. *Neuron*. 2016;90(1):11–25.
76. Hartmann T, et al. A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. *J Alzheimers Dis*. 2014; 41(3):715–7.
77. Whiley L, et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. *Neurobiol Aging*. 2014;35(2):271–8.
78. Toledo JB, et al. Metabolic network failures in Alzheimer's disease: a biochemical road map. *Alzheimers Dement*. 2017;13(9):965–84.
79. Mapstone M, et al. Plasma phospholipids identify antecedent memory impairment in older adults. *Nat Med*. 2014;20(4):415–8.
80. Newsom SA, et al. Skeletal muscle phosphatidylcholine and phosphatidylethanolamine are related to insulin sensitivity and respond to acute exercise in humans. *J Appl Physiol*. 2016;120(11):1355–63.
81. Wang-Sattler R, et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans - first results from the KORA study. *PLoS One*. 2008;3(12):e3863.
82. Aalling NN, Nedergaard M, DiNuzzo M. Cerebral metabolic changes during sleep. *Curr Neurol Neurosci Rep*. 2018;18(9):57.
83. Rijpma A, et al. The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial. *Alzheimers Res Ther*. 2017;9(1):51.
84. van Wijk N, et al. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. *Alzheimers Dement (Amst)*. 2017;8:139–46.
85. Wurtman RJ, et al. Use of phosphatide precursors to promote synaptogenesis. *Annu Rev Nutr*. 2009;29:59–87.
86. Freund-Levi Y, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegaAD study: a randomized double-blind trial. *Arch Neurol*. 2006;63(10):1402–8.
87. Quinn JF, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA*. 2010;304(17):1903–11.
88. Phillips MA, et al. No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: a randomised controlled trial. *Int J Mol Sci*. 2015;16(10): 24600–13.
89. Thal LJ, et al. Choline chloride fails to improve cognition of Alzheimer's disease. *Neurobiol Aging*. 1981;2(3):205–8.
90. Fisman M, et al. Double blind study of lecithin in patients with Alzheimer's disease. *Can J Psychiatry*. 1981;26(6):426–8.
91. Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One*. 2010;5(9):e12244.
92. Aisen PS, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. *JAMA*. 2008;300(15): 1774–83.
93. Airt S, et al. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. *Neurochem Res*. 2012;37(12):2706–14.
94. Galasko DR, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch Neurol*. 2012;69(7):836–41.
95. Remington R, et al. A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease. *J Alzheimers Dis*. 2015;45(2):395–405.
96. Zhang YP, et al. DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial. *J Neurol Neurosurg Psychiatry*. 2018;89(4):382–8.
97. Olde Rikkert MG, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. *J Alzheimers Dis*. 2015;44(2):471–80.
98. Cummings J, et al. Effect size analyses of souvenaid in patients with Alzheimer's disease. *J Alzheimers Dis*. 2017;55(3):1131–9.
99. Cohen J. The t test for means. In: *Statistical power analysis for the behavioral sciences*. 2nd ed. Mahwah: Cohen JL, Lawrence Erlbaum Associates; 1988. p. 19–74.
100. Onakpoya IJ, Heneghan CJ. The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. *Nutr Neurosci*. 2017; 20(4):219–27.
101. Rijpma A, et al. The effect of Souvenaid on brain phospholipid metabolism in patients with mild Alzheimer's disease: results of a randomised controlled 31P-magnetic resonance spectroscopy study. *Neurobiol Aging*. 2016; 39(Suppl 1):S7–8.
102. de Waal H, et al. The effect of Souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. *PLoS One*. 2014;9(1):e86558.
103. van Straaten EC, et al. Magnetoencephalography for the detection of intervention effects of a specific nutrient combination in patients with mild Alzheimer's disease: results from an exploratory double-blind, randomized, controlled study. *Front Neurol*. 2016;7:161.
104. Visser PJ, et al. Effects of Fortasyn Connect (Souvenaid) on longitudinal brain atrophy measures in prodromal Alzheimer's disease: results of the double-blind randomised controlled Lipididiet trial. *Alzheimers Dement*. 2016;12:P1135–6.
105. Bianchetti A, et al. Effectiveness of a specific nutritional supplement on cognitive, behavioral and functional symptoms in mild cognitive impairment and Alzheimer's dementia: caregivers judgments. Results of an observational survey. *J Gerontol Geriatr*. 2018;66:68–74.
106. Chu LW. Effectiveness and tolerability of Souvenaid in Chinese patients with mild Alzheimer's disease and other dementias in a real-world clinic setting: an open-label study. *Alzheimers Dement*. 2017;13(7):P930.
107. Kalisvaart CJ, Vreeswijk R. P051: Souvenaid in a real-life prospective clinical setting. *Eur Geriatr Med*. 2014;5(Suppl 1):S98.
108. Schwab A, et al. Retrospektive Arzt- und Patientenbefragungen zu Souvenaid, einer medizinischen Ernährung zur Behandlung der Alzheimer-Krankheit im Frühstadium. Kongress der Deutschen Gesellschaft für Neurologie (DGN) 2014. poster P298.
109. Aguilar M, Soler P. Souvenaid in cognitive deterioration. our experience after 5 years of treatment and follow-up. *J Prev Alzheimers Dis*. 2018; 5(Suppl1):S167 (LBP17).
110. Manzano Palomo MS, et al. Mild cognitive impairment with a high risk of progression to Alzheimer's disease dementia (MCI-HR-AD): effect of Souvenaid((R)) treatment on cognition and (18) F-FDG PET scans. *J Alzheimers Dis Rep*. 2019;3:95–102.
111. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med*. 2004;256(3):183–94.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.